Compare iShares MSCI ACWI ETF (ACWI) vs Nuvalent Inc (NUVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Nuvalent Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.53, while Nuvalent Inc trades at $123.81 (market cap $9.80B). The key difference: Nuvalent Inc is trading nearer its 52-week high, iShares MSCI ACWI ETF nearer its low. Which is the better fit depends on your goals.
| ACWI | NUVL | |
|---|---|---|
52-Week High | $159.97 | $123.77 |
52-Week Low | $128.32 | $72.16 |
Market Cap | — | $9.80B |
Sector | — | Technology |
Enterprise Value | — | $8.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Nuvalent (NUVL) trades at $123.72, down slightly by 0.01% on the day, with a price-to-book ratio of 8.34. The stock exhibits a bullish technical trend, supported by strong moving averages, though RSI levels indicate overbought conditions. Recent financials show negative profitability, with a net loss of $425.38 million in 2025 and negative operating cash flow, but the company secured $515.34 million in financing. A major development is the pending $10.6 billion acquisition by GSK at $124 per share, announced in June 2026, which has driven significant investor attention and legal scrutiny over fairness.
The outlook for NUVL is heavily influenced by the GSK acquisition, offering a near-term exit at $124 per share. Risks include ongoing shareholder investigations into the deal's fairness and the company's persistent losses. Analyst sentiment is mixed, with 42% recommending buy and 58% hold, reflecting uncertainty around the acquisition's completion and valuation. Investors should monitor regulatory approvals and any competing offers that may emerge, as these will determine final shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
